Illumina vs ResMed

Illumina (ILMN), health care, and ResMed (RMD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

ResMed is worth $33.5B on the stock market and Illumina $30.6B: ResMed is valued at 9% more. Illumina trades at 34.9 times earnings and ResMed at 21.7; operating margins in their latest fiscal years were 18.6% and 33.4%. Over the past year Illumina's share price has moved +62.3% and ResMed's -3.26%.

Key facts

Illumina market value
$30.6B
ResMed market value
$33.5B
Illumina P/E
34.9
ResMed P/E
21.7
Illumina revenue
$4.3BFY to 2025-12-28
ResMed revenue
$5.7BFY to 2026-06-30
Superinvestors holding both
0

Market values as of .

Illumina vs ResMed: every measure side by side
Measure Illumina ResMed
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-282026-06-30
Size
Market cap$30.6Blower$33.5Bhigher
Revenue$4.3Blower$5.7Bhigher
Earnings$850Mlower$1.5Bhigher
Employees8,600lower11,370higher
Total assets$6.6Blower$9Bhigher
Valuation
P/E34.9higher21.7lower
P/S7.1higher5.9lower
P/B9.8higher5.6lower
Dividend yield0.00%lower1.03%higher
Profitability
Operating margin18.6%lower33.4%higher
Balance sheet
Net assets$2.7Blower$6.6Bhigher
Total liabilities$3.9Bhigher$2.4Blower
Total debt—$659.4M
Cash on hand$1.4Blower$1.5Bhigher
Price change
Today+2.33%higher-0.14%lower
1 year+62.3%higher-3.26%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

ResMed only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns ILMN · Who owns RMD

Further comparisons

Learn

Questions and answers

Which is bigger, Illumina or ResMed?

By market value, ResMed is the larger: $33.5B against $30.6B for Illumina. By revenue in its latest fiscal year, ResMed is the larger: $5.7B against $4.3B for Illumina.

Which has the higher P/E ratio?

Illumina: 34.9, against 21.7 for ResMed. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

ResMed: 33.4%, against 18.6% for Illumina. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

ResMed: 1.03%, against 0.00% for Illumina. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Illumina and ResMed?

None of the tracked superinvestors holds both in their latest 13F filing. 11 hold Illumina and 1 holds ResMed.

Cite this page

Funkfolio, “Illumina vs ResMed”, data as of 18 November 2026. https://funkfolio.com/compare/ilmn-vs-rmd

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.